How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,822 results for

Oral Contraceptive-Related Uterine Bleeding Management

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma. (PubMed)

Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma. To compare ormeloxifene with combined oral contraceptive (COC) in abnormal uterine bleeding (AUB) due to leiomyoma (AUB-L).Fifty women with AUB-L were randomized after informed consent and institute ethics clearance. Group I (n = 25) was given ormeloxifene (a SERM i.e. selective estrogen receptor modulator) 60 mg twice per week and group II (n = 25) was given COC (ethinyl

2017 The journal of obstetrics and gynaecology research

2. Oral Contraceptive-Related Uterine Bleeding Management

Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse (...) Cancer Administration 4 Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Aka: Oral Contraceptive-Related Uterine Bleeding Management II. Management: Overall approach to OCP associated uterine bleeding Consider evaluation Evaluate for missed OCP doses Counsel on compliance Anticipate uterine bleeding in first 3 months Offer anticipatory guidance Consider adjuncts to 800 mg PO tid for 1-2 weeks Supplemental for 1-2 weeks Premarin 0.625

2018 FP Notebook

3. Abnormal Uterine Bleeding in Pre-Menopausal Women

by the Executive and Council of the SOGC. Results This document provides a summary of up-to-date evidence regarding diagnosis, investigations, and medical and surgical management of AUB. The resulting recommendations may be adapted by individual health care workers when serving women with this condition. Conclusions Abnormal uterine bleeding is a common and sometimes debilitating condition in women of reproductive age. Standardization of related terminology, a systematic approach to diagnosis and investigation (...) treatment for abnormal uterine bleeding. 10 Abnormal uterine bleeding secondary to submucosal fibroids may be managed by hysteroscopic myomectomy. 11 Inherited bleeding disorders may be an underlying cause of abnormal uterine bleeding, with von Willebrand's disease present in the majority of cases (II-2). 12 Acute heavy menstrual bleeding may result in significant anemia and emergent care (III). 13 Abnormal uterine bleeding in the adolescent most commonly represents ovulatory dysfunction related

2018 Society of Obstetricians and Gynaecologists of Canada

4. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding

, such as an examination under anesthesia. After correction of acute heavy menstrual bleeding, maintenance hormonal therapy can include combined hormonal contraceptives, oral and injectable progestins, and levonorgestrel-releasing intrauterine devices. Obstetrician–gynecologists can provide important guidance to premenarchal and postmenarchal girls and their families about issues related to menses and should counsel all adolescent patients with a bleeding disorder about safe medication use and future surgical (...) should be reserved for those who do not respond to medical therapy. Adolescents who are hemodynamically unstable or actively bleeding heavily should be hospitalized for management. In the absence of contraindications to estrogen, hormonal therapy for acute heavy menstrual bleeding can consist of intravenous conjugated estrogen every 4–6 hours; alternatively, monophasic combined oral contraceptive pills (OCPs) (in 30–50 microgram ethinyl estradiol formulation) can be used every 6–8 hours until

2019 American College of Obstetricians and Gynecologists

5. Abnormal Uterine Bleeding and Progestin-only Contraceptives

Abnormal Uterine Bleeding and Progestin-only Contraceptives Abnormal Uterine Bleeding and Progestin-only Contraceptives - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Abnormal Uterine Bleeding (...) Enrollment : 300 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention Official Title: Predictors of Abnormal Uterine Bleeding in Progestin-only Contraceptives Users Estimated Study Start Date : June 2018 Estimated Primary Completion Date : January 2019 Estimated Study Completion Date : February 2019 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm

2018 Clinical Trials

6. Heavy menstrual bleeding: assessment and management

Recognise that heavy menstrual bleeding (HMB) has a major impact on a woman's quality of life, and ensure that any intervention aims to improve this rather than focusing on blood loss. [2007] [2007] 1.2 History, physical examination and laboratory tests History History 1.2.1 T ake a history from the woman that covers: the nature of the bleeding related symptoms, such as persistent intermenstrual bleeding, pelvic pain and/or pressure symptoms, that might suggest uterine cavity abnormality, histological (...) of HMB without other related symptoms (see recommendation 1.2.1), consider pharmacological treatment without carrying Heavy menstrual bleeding: assessment and management (NG88) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 36out a physical examination (unless the treatment chosen is levonorgestrel- releasing intrauterine system [LNG IUS] [1] ). [2007, amended 2018] [2007, amended 2018] Ph Physical e ysical

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users

The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03264781

2017 Clinical Trials

8. Primary care management of abnormal uterine bleeding

. This appeared to be a well conducted review. The authors' conclusions reflect the evidence and appear reliable. The small proportion of good quality trials should be borne in mind. Implications of the review for practice and research Practice : The authors stated that contraceptive options such as LNG-IUS and combined oral contraceptives were proven options for helping with management of abnormal uterine bleeding. Agents like metformin may also be considered for women with polycystic ovary syndrome (...) in the review: 10 studies on irregular uterine bleeding and 29 studies on abnormal cyclic uterine bleeding. Studies of irregular uterine bleeding were classified as being of good (two studies), fair (two studies) and poor quality (six studies). Studies on abnormal cyclic uterine bleeding were classified as being of good (four studies), fair (eight studies) and poor quality (17 studies). Women with irregular uterine bleeding (10 studies) : Metformin, metformin with exenatide and tricyclic oral contraceptive

2013 DARE.

9. Abnormal uterine bleeding: managing endometrial dysfunction and leiomyomas. (PubMed)

intrauterine devices for heavy menstrual bleeding is increasing in Australia, and they are considered first-line medical management for women accepting of hormonal therapies. Tranexamic acid, non-steroidal anti-inflammatory drugs, the combined oral contraceptive pill and oral progestins offer alternatives. Hysterectomy offers a definitive surgical approach to abnormal uterine bleeding and is associated with high levels of patient satisfaction. Women wishing to preserve their fertility, or avoid (...) Abnormal uterine bleeding: managing endometrial dysfunction and leiomyomas. Abnormal uterine bleeding refers to any change in the regularity, frequency, heaviness or length of menstruation. There are several potential causes for bleeding disturbance, the two most common being primary endometrial dysfunction and fibroids. Management of abnormal uterine bleeding involves both medical and surgical options and will largely depend on a patient's fertility plans. The use of levonorgestrel-releasing

2018 Medical Journal of Australia

10. Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey. (PubMed)

Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey. The optimal management of oral contraception and menstrual bleeding during treatment of venous thromboembolism (VTE) is largely unknown. We aimed to elicit expert opinion and compare that to current practice as assessed by a world-wide international web-based survey among (...) on treating patients with anticoagulation-associated abnormal uterine bleeding with tranexamic acid, although this is not supported by strong evidence from the literature. No consensus was reached on the optimal anticoagulant drug class.International experts' opinions on handling of contraceptives and management of anticoagulant-associated abnormal uterine bleeding in female VTE patients are divergent and management in clinical practice is heterogeneous. There is a great need of further studies

2017 Thrombosis research

11. Gynaecological and Obstetric Management of Women With Inherited Bleeding Disorders

menorrhagia is consistently reported to be 10% to 20% and is even higher in adolescents presenting with menorrhagia. Options Diagnostic tools and specific medical and, where appropriate, surgical alternatives to management are reviewed and evidence-based recommendations presented. Evidence A MEDLINE search of the English literature between January 1975 and November 2003 was performed using the following key words: menorrhagia, uterine bleeding, pregnancy, von Willebrand, congenital bleeding disorder (...) , desmopressin/DDAVP, tranexamic acid, oral contraceptives, medroxyprogesterone, therapy, hysterectomy, anesthesia, epidural, spinal. Recommendations from other society guidelines were reviewed. Values The quality of evidence reported in this document has been described USing the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Preventive Health Exam ( Table 1 ). 13 Recommendations 1. Inherited bleeding disorders should be considered in the differential diagnosis

2018 Society of Obstetricians and Gynaecologists of Canada

12. Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/ Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/ Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/ Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/ Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women The safety and scientific validity of this study is the responsibility

2017 Clinical Trials

13. Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

management is considered the first line of medical therapy for patients with acute AUB without known or suspected bleeding disorders. Treatment options include IV conjugated equine estrogen, combined oral contraceptives (OCs), and oral progestins. In one randomized controlled trial of 34 women, IV conjugated equine estrogen was shown to stop bleeding in 72% of participants within 8 hours of administration compared with 38% of participants treated with a placebo ( ). Little data exist regarding the use (...) of dysfunctional uterine bleeding—a double-blind randomized control study. Obstet Gynecol 1982;59: 285–91. 25 mg IV Every 4–6 hours for 24 hours Contraindications include, but are not limited, to breast cancer, active or past venous thrombosis or arterial thromboembolic disease, and liver dysfunction or disease. The agent should be used with caution in patients with cardiovascular or thromboembolic risk factors. Combined oral contraceptives † Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral

2013 American College of Obstetricians and Gynecologists

14. The use of viscoelastic haemostatic assays in the management of major bleeding

The use of viscoelastic haemostatic assays in the management of major bleeding The use of viscoelastic haemostatic assays in the management of major bleeding - Curry - 2018 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access The use of viscoelastic (...) haemostatic assays in the management of major bleeding A British Society for Haematology Guideline Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK NIHR BRC, Blood Theme, Oxford University, Oxford, UK Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London, UK Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK NIHR BRC, Blood Theme, Oxford University, Oxford, UK Department of Anaesthesia, Royal Free

Full Text available with Trip Pro

2018 British Committee for Standards in Haematology

15. Radiologic Management of Uterine Leiomyomas

. Pharmaceutical Treatment The least invasive treatment option remains medical therapy with either oral contraceptive medication or gonadotropin-releasing hormone (GnRH) agonists/antagonists. Oral contraceptives may manage bleeding symptoms effectively, especially in women with small fibroids. GnRH agonists have been shown in several studies not only to be effective against symptoms of bleeding but also to result in reduction in uterine volume and myoma volume, making them effective against bulk-related (...) to treat the symptoms of the fibroids, such as abnormal uterine bleeding, bulk-related symptoms, and/or pain. Approximately 1 in 350 women undergoing hysterectomy or myomectomy for the treatment of fibroids is found to have an unsuspected uterine sarcoma [2]. Discussion by Variant Variant 1: Middle-aged woman with multiple uterine fibroids resulting in a 20-week-sized uterus on physical examination and menorrhagia. Bulk symptoms of urinary frequency and bloating are present. The patient has a recent

2017 American College of Radiology

16. Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products

withdrawal bleeding and may also shed the retained products of conception and avoid a surgical procedure with its related potential complications. Condition or disease Intervention/treatment Phase Retained Products of Conception Post Abortion Drug: Oral contraceptive Other: Expectant management Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel (...) Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

17. Oral Contraceptive-Related Uterine Bleeding Management

Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse (...) Cancer Administration 4 Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Aka: Oral Contraceptive-Related Uterine Bleeding Management II. Management: Overall approach to OCP associated uterine bleeding Consider evaluation Evaluate for missed OCP doses Counsel on compliance Anticipate uterine bleeding in first 3 months Offer anticipatory guidance Consider adjuncts to 800 mg PO tid for 1-2 weeks Supplemental for 1-2 weeks Premarin 0.625

2015 FP Notebook

18. Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women The safety and scientific validity of this study is the responsibility of the study sponsor

2016 Clinical Trials

19. Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study) Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study) The safety and scientific validity of this study

2016 Clinical Trials

20. Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception

; however, a small increase in contraceptive failure in women with a body mass index greater than 30 cannot be excluded (II-2). 3. Combined oral contraceptive pills are associated with a number of non-contraceptive benefits, including but not limited to decreased menstrual bleeding, decreased acne, fewer endometriosis-related symptoms, and a decreased risk of ovarian and endometrial cancers (II-2). 4. Combined oral contraceptive pills (COCs) are associated with an increased risk of venous (...) . Back-up contraception (barrier method) or abstinence should be used for the first 7 consecutive days of CHC use unless CHC was initiated on the first day of menses (I-A). 3. Health care providers should consider the possibility of irregular pill taking, concomitant medication use, malabsorption, uterine or cervical pathology, pregnancy, or chlamydial infection in women presenting with persistent unscheduled bleeding on the combined oral contraceptive pill (III-A). 4. If 1 combined oral

2017 Society of Obstetricians and Gynaecologists of Canada

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>